Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01080209 · ClinicalTrials.gov registry record · Phase 2
Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
NCT01080209 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 215 participants.
The verdict
NCT01080209, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
Study Summary
This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.
Interventions
- OTHER Sham
- DRUG Brimo PS DDS®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01080209
The ClinicalTrials.gov registry entry for NCT01080209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT01080209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01080209 about?
NCT01080209 is a clinical study titled "Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System". This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.
What is the current status of trial NCT01080209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2010-02. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01080209?
The interventions under investigation include: Sham (OTHER), Brimo PS DDS® (DRUG).
Who is sponsoring clinical trial NCT01080209?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.